WHO approves emergency use of CanSino vaccine against Covid-19

Get real time updates directly on you device, subscribe now.

The World Health Organization (WHO) approved, this Thursday (19), the emergency use of the Convidencia vaccine, against Covid-19, produced by the CanSino laboratory, in China.

The Convidencia vaccine uses a modified human adenovirus that expresses the Spike protein of SARS-CoV-2, with the aim of inducing the immune response in the body. The immunizer is administered in a single dose.

The immunizer is the 11th approved by the WHO after evaluating the quality, safety and efficacy, a prerequisite for the supply of the vaccine by the international consortium Covax Facility (see the list ). According to the WHO, the authorization also allows countries to speed up regulatory approval processes to import and administer the vaccines.

The assessment process includes a review of data on quality, safety, efficacy, a risk management plan, programmatic suitability, and a WHO manufacturing site inspection.

The Technical Advisory Group on Emergency Use Listing, convened by the WHO and composed of regulatory experts from around the world, determined that the vaccine meets the entity’s standards for protection against Covid-19 and that the benefits of the vaccine far outweigh the scratchs.

The vaccine also underwent review by the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), which formulates specific vaccine policies and recommendations for the use of immunizers in populations.

SAGE recommends the use of the vaccine in a single dose (0.5 ml), in all age groups over 18 years. The immunizer was shown to be 64% effective against symptomatic disease and 92% against severe Covid-19.

In Brazil

The National Health Surveillance Agency (Anvisa) received the request for emergency use of the Convidecia vaccine, on November 10th. The request was presented by the Biomm laboratory, representative in Brazil of the manufacturer of the vaccine produced in China.

On May 13, Anvisa received the application for registration of the Convidecia vaccine. According to the agency, the request is already being evaluated by the technical areas involved and the analysis period is 60 days.

Source: CNN Brasil

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.

www xxx xxx video tube freeproncom filmsex hindi xxxvdo xxx hd
buy kamagra buy kamagra online $255 payday loans online same day no denial payday loans direct lenders only